Bristol Keeps Focus On Opdivo In Lung Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Now that the PD-1 inhibitor has a melanoma approval under its belt, Bristol-Myers is moving full steam ahead with the development of Opdivo with 11 lung cancer clinical trials ongoing or planned.
You may also be interested in...
Bristol’s Next CEO Is Caforio, Tasked With Leading Immuno-Oncology Charge
Bristol CEO Lamberto Andreotti will step down as CEO in May but remain as chairman of the board, making way for insider Giovanni Caforio to take over the top slot. His task will be overseeing Bristol’s transition to a commercial-stage immuno-oncology powerhouse.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
Zafgen Drops Beloranib, But Its New Focus Raises Doubts
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.